 |
|
|
|||||||
|
DiaKine Therapeutics, Inc. is a development-stage company commercializing novel immune anti-inflamatory modulators into therapies for diabetes and related complications. These drugs have the potential to stop the progression of diabetes and reverse damage already caused by the disease. Therapeutics under development by DiaKine include: · Adjunct to islet cell transplants · Halt the progression of type 1 diabetes in newly diagnosed adults. · Treatment and prevention of insulin requiring type 2 diabetic · Treatment and prevention of diabetes complications · Treatment to halt inflammation linked to atherosclerosis and autoimmune disease For more information, please contact us at info@diakine.com. |
|||||||||
|
©2012 DiaKine Therapeutics. All rights reserved.
|
|||||||||
